Tilray Brands

Secular Legalization And Wellness Trends Will Transform EU Cannabis Industry

AnalystHighTarget

Not Invested

Consensus Narrative from 9 Analysts

Published

20 Aug 25

Updated

20 Aug 25

AnalystHighTarget's Fair Value

US$1.50

26.0% undervalued

20 Aug

US$1.11

-40.6%

-5.9%

Author's Valuation

US$1.5

26.0% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$1.5

26.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

4.46%

Pharma revenue growth rate

0.55%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.45%

Calculation

US$222.11m

Earnings '28

10.96x

PE Ratio '28

US$2.43b

Market Cap '28

US$2.43b

Market Cap '28

1.35b

No. shares '28

US$1.81

Share Price '28

US$1.81 Share Price '28

Discounted to 2025 @ 6.45% p.a.

US$1.50

Fair Value '25